MarketCap
Facebook
X
Telegram
Castle Biosciences Balance Sheet 2025-2011 | CSTL
Brief overview of Castle Biosciences's balance sheet strength
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
The balance sheet expanded from $462.6 million to $578.6 million. Growth of +25.1% and CAGR of 5.8% look measured and sustainable.
Asset growth of +25.1% came with a +111.8% rise in liabilities. Financial leverage became more prominent.
Internal capital represents 81.4% of the balance sheet, previously 89%. This is a strong capital position.
Negative net debt of -$105.8 million means cash holdings are larger than debt obligations.
Cash represents 20.2% of assets versus 71.3% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$224.3 million. It should be assessed alongside historical profits and capital distributions.
Conclusion
Castle Biosciences's balance sheet sends more positive than negative signals, but liabilities should not begin outpacing the capital base.
Annual Balance Sheet Castle Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-106 M | -108 M | -97.7 M | -121 M | -328 M | -410 M | -73.7 M | 20 M | 17.4 M | - | - | - | - | - | - |
Long Term Debt |
9.64 M | 9.74 M | 25 K | 90 K | 124 K | - | 19.3 M | 24.5 M | 17.6 M | - | - | - | - | - | - |
Long Term Debt Current |
1.32 M | 1.66 M | 1.14 M | 1.78 M | 1.18 M | - | 5.83 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 2.76 M | 19.3 M | 25.7 M | 18.9 M | - | - | - | - | - | - |
Total Current Liabilities |
68.7 M | 49.4 M | 47.7 M | 36.1 M | 24.9 M | 20.9 M | 15.3 M | - | - | - | - | - | - | - | - |
Total Liabilities |
108 M | 75.4 M | 62.1 M | 48.2 M | 50.8 M | 23.6 M | 34.6 M | 32.5 M | 24.1 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 6.62 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-224 M | -200 M | -218 M | -161 M | -93.8 M | -62.5 M | -52.2 M | -57.5 M | -51.1 M | - | - | - | - | - | - |
Total Assets |
579 M | 531 M | 453 M | 447 M | 463 M | 439 M | 120 M | 22.4 M | 9.82 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
117 M | 120 M | 98.8 M | 123 M | 330 M | 410 M | 98.8 M | 4.48 M | - | - | - | - | - | - | - |
Book Value |
471 M | 456 M | 391 M | 399 M | 412 M | 416 M | 85.1 M | -10.1 M | -14.3 M | - | - | - | - | - | - |
Total Shareholders Equity |
471 M | 456 M | 391 M | 399 M | 412 M | 416 M | 85.1 M | -56.6 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Castle Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
7.16 M | 8.4 M | 10 M | 8.1 M | 8.92 M | 9.74 M | 10 M | 10 M | 10 M | - | 13.4 M | 12.4 M | 11.1 M | 11.5 M | 11.9 M | 6.48 M | 6.71 M | 6.9 M | - | - | - | - | 12.5 M | 14.7 M | 17 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 24.5 M | 24.5 M | 24.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
91.1 M | 86.4 M | 95.7 M | 89.4 M | 61.4 M | 75.4 M | 73.5 M | 63.4 M | 56 M | 62.1 M | 50.2 M | 46.6 M | 41.7 M | 48.2 M | 46.4 M | 36.7 M | 47.1 M | 50.8 M | 22 M | 19.6 M | 18.7 M | 23.6 M | 23.6 M | 23.6 M | 23.6 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 32.5 M | 32.5 M | 32.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 M | 6.18 M | 8.18 M | 6.62 M | 6.62 M | 6.62 M | 6.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-241 M | -239 M | -222 M | -221 M | -226 M | -200 M | -210 M | -212 M | -221 M | -218 M | -216 M | -209 M | -190 M | -161 M | -140 M | -120 M | -118 M | -93.8 M | -87.4 M | -75.6 M | -66.8 M | -62.5 M | -62.5 M | -62.5 M | -62.5 M | -52.2 M | -52.2 M | -52.2 M | -52.2 M | -57.5 M | -57.5 M | -57.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
561 M | 548 M | 563 M | 545 M | 502 M | 531 M | 515 M | 487 M | 459 M | 453 M | 436 M | 425 M | 427 M | 447 M | 458 M | 458 M | 444 M | 463 M | 434 M | 436 M | 437 M | 439 M | 439 M | 439 M | 439 M | 120 M | 120 M | 120 M | 120 M | 22.4 M | 22.4 M | 22.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
62.1 M | 63.8 M | 85.6 M | 82.2 M | 89.7 M | 120 M | 95 M | 85.6 M | 82.9 M | 98.8 M | 91.2 M | 95.9 M | 115 M | 123 M | 134 M | 273 M | 309 M | 330 M | 363 M | 368 M | 407 M | 410 M | 410 M | 410 M | 410 M | 98.8 M | 98.8 M | 98.8 M | 98.8 M | 4.48 M | 4.48 M | 4.48 M | - | 1.21 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
470 M | 461 M | 467 M | 455 M | 440 M | 456 M | 441 M | 424 M | 402 M | 391 M | 386 M | 379 M | 385 M | 399 M | 411 M | 422 M | 397 M | 412 M | 412 M | 416 M | 419 M | 416 M | 416 M | 416 M | 416 M | 85.1 M | 85.1 M | 85.1 M | 85.1 M | -10.1 M | -10.1 M | -10.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
470 M | 461 M | 467 M | 455 M | 440 M | 456 M | 441 M | 424 M | 402 M | 391 M | 386 M | 379 M | 385 M | 399 M | 411 M | 422 M | 397 M | 412 M | 412 M | 416 M | 419 M | 416 M | 416 M | 416 M | 416 M | 85.1 M | 85.1 M | 85.1 M | 85.1 M | -56.6 M | -56.6 M | -56.6 M | -53.9 M | -50.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Castle Biosciences, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Niderland
Germany
Israel
Britain
Canada
China
Australia
Schweiz
Irlanda
